Berlin-Chemie AG granted licensing rights by the Helsinn Group for ONICIT®/ALOXI® and AKYNZEO®

Berlin-Chemie AG granted licensing rights by the Helsinn Group for ONICIT®/ALOXI® and AKYNZEO®

An affiliate of the Menarini Group based in Germany, Berlin-Chemie AG has been granted licensing rights for the commercialization of ONICIT® as well as AKYNZEO® in Russia along with the CIS region to avert nausea and vomiting brought along by chemotherapy, by a Swiss pharmaceutical firm, Helsinn Group, which is dedicated to developing quality cancer care goods.

A set dose combination anti-emetic therapy, AKYNZEO® addresses critical pathways of acute and stalled nausea and vomiting induced by chemotherapy, both. In last year’s October, AKYNZEO® was approved for registration in Russian. The drug is set to launch in Russia this year.

On the other hand, in 2011, an anti-emetic for the inhibition of chemotherapy-induced nausea and vomiting, ONICIT® saw its approval for registration. The drug is set to be relaunched alongside AKYNZEO®.

Aside from Russia, the licensing contracts with Berlin-Chemie apply to other nations as well. These include Belarus, Kyrgyzstan, Armenia, Ukraine, Tajikistan, Kazakhstan, Azerbaijan, Uzbekistan, Moldova, Georgia, and Turkmenistan.

AKYNZEO® has managed to acquire registration in Kazakhstan as well as Ukraine, whereas ALOXI® has registration in Ukraine.

Under the contract, all global development rights will be held by Helsinn. These include clinical development operations as well as the supply of ONICIT® and AKYNZEO® both. The exclusive rights to advance, deal, and market ONICIT® and AKYNZEO® will lie with Berlin-Chemie for all nations included in their respective allotted territories.

The chairman and chief executive officer of the Helsinn Group, Riccardo Braglia stated how they were pleased to have entered into the contract with Berlin-Chemie, which has established a recognizable and sturdy position for itself in Russia as well as the CIS region. He added how this was a significant move for cancer patients throughout Russia and the CIS region.

, ,